Morepen Laboratories Submits First U.S. ANDA for Sitagliptin Tablets
Morepen Laboratories Ltd · Press Release · 28 Sept 2026, 2:23 pm
Morepen Laboratories Submits First U.S. ANDA for Sitagliptin Tablets Morepen Laboratories has filed its first U.S. ANDA (No. 221758) on 25th Sep'26 with the USFDA for Sitagliptin Tablets USP (25 mg, 50 mg, and 100 mg), marking a key shift into integrated finished dosage CDMO services. Sitagliptin, an oral Type 2 diabetes treatment (innovator Januvia), recorded global sales of ~$1.604 billion in '25. The drug's U.S. patent expires on 24th Nov'26, with pediatric exclusivity extending to 24th May'27. Morepen estimates approval and commercial supply within 24–36 months, subject to regulatory reviews and inspections.
Original exchange filing (PDF)
More announcements from Morepen Laboratories Ltd
- Update on Credit Rating · 14 Nov 2026
- Please find attached the Press Release · 09 Nov 2026
- Change in Senior Management Personnel on account of resignation · 31 Oct 2026
- Change in Designation of Senior Management Personnel of the Company · 28 Oct 2026
- Please find attached the monitoring agency report for the quarter ended September 30, 2026 · 27 Oct 2026
- Please find attached the Investor Presentation for Q2 & H1 FY 27 Financial Results · 27 Oct 2026
- Please find attached the press release · 27 Oct 2026
- Please find attached the Q2 & H1 FY 27 Financial Results · 27 Oct 2026
